Atlas Trials

Autophagy Inhibition to Augment Mammilian Target of Rapamycin (mTOR) Inhibition: A Phase I/II Trial of RAD001 and Hydroxychloroquine (HCQ) in Patients With Previously Treated Renal Cell Carcinoma

Clinical trial NCT01510119 · COMPLETED

Trial details

NCT number
NCT01510119
Sponsor
Abramson Cancer Center at Penn Medicine
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Metastatic Clear Cell Renal Cell Carcinoma
Start date
2011-09-01
Primary completion
2016-04-04
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.